Cargando…
The Omicron Variant Reinfection Risk among Individuals with a Previous SARS-CoV-2 Infection within One Year in Shanghai, China: A Cross-Sectional Study
Reinfection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variants due to immune escape is challenging for the global response to the pandemic. We estimated the Omicron reinfection prevalence among people who had a previous SARS-CoV-2 infection in Shanghai, China. We conducted a...
Autores principales: | , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10386598/ https://www.ncbi.nlm.nih.gov/pubmed/37514962 http://dx.doi.org/10.3390/vaccines11071146 |
_version_ | 1785081707263688704 |
---|---|
author | Ye, Chuchu Zhang, Ge Zhang, Anran Xin, Hualei Wu, Kang Li, Zhongjie Jia, Yilin Hao, Lipeng Xue, Caoyi Wang, Yuanping Xu, Hongmei Zhu, Weiping Zhou, Yixin |
author_facet | Ye, Chuchu Zhang, Ge Zhang, Anran Xin, Hualei Wu, Kang Li, Zhongjie Jia, Yilin Hao, Lipeng Xue, Caoyi Wang, Yuanping Xu, Hongmei Zhu, Weiping Zhou, Yixin |
author_sort | Ye, Chuchu |
collection | PubMed |
description | Reinfection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variants due to immune escape is challenging for the global response to the pandemic. We estimated the Omicron reinfection prevalence among people who had a previous SARS-CoV-2 infection in Shanghai, China. We conducted a telephone survey in December 2022 with those who had previously been infected with Omicron between March and May 2022. Information on their demographics, coronavirus disease 2019 (COVID-19) testing, and vaccination history was collected. The overall and subgroup reinfection rates were estimated and compared. Among the 1981 respondents who were infected between March and May 2022, 260 had positive nucleic acid or rapid antigen tests in December 2022, with an estimated reinfection rate of 13.1% (95% confidence interval [95% CI]: 11.6–14.6). The reinfection rate for those who had a booster vaccination was 11.4% (95% CI: 9.2–13.7), which was significantly lower than that for those with an incomplete vaccination series (15.2%, 95% CI: 12.3–18.1) (adjusted odds ratio [aOR]: 0.579; 95% CI: 0.412–0.813). Reinfection with the Omicron variant was lower among individuals with a previous SARS-CoV-2 infection and those who had a booster vaccination, suggesting that hybrid immunity may offer protection against reinfection with Omicron sublineages. |
format | Online Article Text |
id | pubmed-10386598 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-103865982023-07-30 The Omicron Variant Reinfection Risk among Individuals with a Previous SARS-CoV-2 Infection within One Year in Shanghai, China: A Cross-Sectional Study Ye, Chuchu Zhang, Ge Zhang, Anran Xin, Hualei Wu, Kang Li, Zhongjie Jia, Yilin Hao, Lipeng Xue, Caoyi Wang, Yuanping Xu, Hongmei Zhu, Weiping Zhou, Yixin Vaccines (Basel) Article Reinfection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variants due to immune escape is challenging for the global response to the pandemic. We estimated the Omicron reinfection prevalence among people who had a previous SARS-CoV-2 infection in Shanghai, China. We conducted a telephone survey in December 2022 with those who had previously been infected with Omicron between March and May 2022. Information on their demographics, coronavirus disease 2019 (COVID-19) testing, and vaccination history was collected. The overall and subgroup reinfection rates were estimated and compared. Among the 1981 respondents who were infected between March and May 2022, 260 had positive nucleic acid or rapid antigen tests in December 2022, with an estimated reinfection rate of 13.1% (95% confidence interval [95% CI]: 11.6–14.6). The reinfection rate for those who had a booster vaccination was 11.4% (95% CI: 9.2–13.7), which was significantly lower than that for those with an incomplete vaccination series (15.2%, 95% CI: 12.3–18.1) (adjusted odds ratio [aOR]: 0.579; 95% CI: 0.412–0.813). Reinfection with the Omicron variant was lower among individuals with a previous SARS-CoV-2 infection and those who had a booster vaccination, suggesting that hybrid immunity may offer protection against reinfection with Omicron sublineages. MDPI 2023-06-25 /pmc/articles/PMC10386598/ /pubmed/37514962 http://dx.doi.org/10.3390/vaccines11071146 Text en © 2023 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Ye, Chuchu Zhang, Ge Zhang, Anran Xin, Hualei Wu, Kang Li, Zhongjie Jia, Yilin Hao, Lipeng Xue, Caoyi Wang, Yuanping Xu, Hongmei Zhu, Weiping Zhou, Yixin The Omicron Variant Reinfection Risk among Individuals with a Previous SARS-CoV-2 Infection within One Year in Shanghai, China: A Cross-Sectional Study |
title | The Omicron Variant Reinfection Risk among Individuals with a Previous SARS-CoV-2 Infection within One Year in Shanghai, China: A Cross-Sectional Study |
title_full | The Omicron Variant Reinfection Risk among Individuals with a Previous SARS-CoV-2 Infection within One Year in Shanghai, China: A Cross-Sectional Study |
title_fullStr | The Omicron Variant Reinfection Risk among Individuals with a Previous SARS-CoV-2 Infection within One Year in Shanghai, China: A Cross-Sectional Study |
title_full_unstemmed | The Omicron Variant Reinfection Risk among Individuals with a Previous SARS-CoV-2 Infection within One Year in Shanghai, China: A Cross-Sectional Study |
title_short | The Omicron Variant Reinfection Risk among Individuals with a Previous SARS-CoV-2 Infection within One Year in Shanghai, China: A Cross-Sectional Study |
title_sort | omicron variant reinfection risk among individuals with a previous sars-cov-2 infection within one year in shanghai, china: a cross-sectional study |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10386598/ https://www.ncbi.nlm.nih.gov/pubmed/37514962 http://dx.doi.org/10.3390/vaccines11071146 |
work_keys_str_mv | AT yechuchu theomicronvariantreinfectionriskamongindividualswithaprevioussarscov2infectionwithinoneyearinshanghaichinaacrosssectionalstudy AT zhangge theomicronvariantreinfectionriskamongindividualswithaprevioussarscov2infectionwithinoneyearinshanghaichinaacrosssectionalstudy AT zhanganran theomicronvariantreinfectionriskamongindividualswithaprevioussarscov2infectionwithinoneyearinshanghaichinaacrosssectionalstudy AT xinhualei theomicronvariantreinfectionriskamongindividualswithaprevioussarscov2infectionwithinoneyearinshanghaichinaacrosssectionalstudy AT wukang theomicronvariantreinfectionriskamongindividualswithaprevioussarscov2infectionwithinoneyearinshanghaichinaacrosssectionalstudy AT lizhongjie theomicronvariantreinfectionriskamongindividualswithaprevioussarscov2infectionwithinoneyearinshanghaichinaacrosssectionalstudy AT jiayilin theomicronvariantreinfectionriskamongindividualswithaprevioussarscov2infectionwithinoneyearinshanghaichinaacrosssectionalstudy AT haolipeng theomicronvariantreinfectionriskamongindividualswithaprevioussarscov2infectionwithinoneyearinshanghaichinaacrosssectionalstudy AT xuecaoyi theomicronvariantreinfectionriskamongindividualswithaprevioussarscov2infectionwithinoneyearinshanghaichinaacrosssectionalstudy AT wangyuanping theomicronvariantreinfectionriskamongindividualswithaprevioussarscov2infectionwithinoneyearinshanghaichinaacrosssectionalstudy AT xuhongmei theomicronvariantreinfectionriskamongindividualswithaprevioussarscov2infectionwithinoneyearinshanghaichinaacrosssectionalstudy AT zhuweiping theomicronvariantreinfectionriskamongindividualswithaprevioussarscov2infectionwithinoneyearinshanghaichinaacrosssectionalstudy AT zhouyixin theomicronvariantreinfectionriskamongindividualswithaprevioussarscov2infectionwithinoneyearinshanghaichinaacrosssectionalstudy AT yechuchu omicronvariantreinfectionriskamongindividualswithaprevioussarscov2infectionwithinoneyearinshanghaichinaacrosssectionalstudy AT zhangge omicronvariantreinfectionriskamongindividualswithaprevioussarscov2infectionwithinoneyearinshanghaichinaacrosssectionalstudy AT zhanganran omicronvariantreinfectionriskamongindividualswithaprevioussarscov2infectionwithinoneyearinshanghaichinaacrosssectionalstudy AT xinhualei omicronvariantreinfectionriskamongindividualswithaprevioussarscov2infectionwithinoneyearinshanghaichinaacrosssectionalstudy AT wukang omicronvariantreinfectionriskamongindividualswithaprevioussarscov2infectionwithinoneyearinshanghaichinaacrosssectionalstudy AT lizhongjie omicronvariantreinfectionriskamongindividualswithaprevioussarscov2infectionwithinoneyearinshanghaichinaacrosssectionalstudy AT jiayilin omicronvariantreinfectionriskamongindividualswithaprevioussarscov2infectionwithinoneyearinshanghaichinaacrosssectionalstudy AT haolipeng omicronvariantreinfectionriskamongindividualswithaprevioussarscov2infectionwithinoneyearinshanghaichinaacrosssectionalstudy AT xuecaoyi omicronvariantreinfectionriskamongindividualswithaprevioussarscov2infectionwithinoneyearinshanghaichinaacrosssectionalstudy AT wangyuanping omicronvariantreinfectionriskamongindividualswithaprevioussarscov2infectionwithinoneyearinshanghaichinaacrosssectionalstudy AT xuhongmei omicronvariantreinfectionriskamongindividualswithaprevioussarscov2infectionwithinoneyearinshanghaichinaacrosssectionalstudy AT zhuweiping omicronvariantreinfectionriskamongindividualswithaprevioussarscov2infectionwithinoneyearinshanghaichinaacrosssectionalstudy AT zhouyixin omicronvariantreinfectionriskamongindividualswithaprevioussarscov2infectionwithinoneyearinshanghaichinaacrosssectionalstudy |